2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 6, 2017

9:00AM-11:00AM: Abstract Number: 1347

Ultrasonography and Synovial Histology in the RA Patients in Remission

Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

9:00AM-11:00AM: Abstract Number: 1350

Ultrasound Detected Tenosynovitis in Rheumatoid Arthritis Patients in Clinical Remission

Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

9:00AM-11:00AM: Abstract Number: 1373

Ultrasound of Subtalar Joint Synovitis in Patients with Rheumatoid Arthritis: Results of an Omeract Reliability Exercise Using Consensual Definitions

Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

9:00AM-11:00AM: Abstract Number: 1391

Ultrasound Response to Tocilizumab in Surgically Replaced Joints and Surgically Operated Joint Areas of Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

9:00AM-11:00AM: Abstract Number: 1119

Uncontrolled Gout Patients with Higher Heart Failure Hospitalization Rates in US

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 1241

Understanding Differences in Patient Definitions of RA Flares Using Omeract Core Domains

Patient Outcomes, Preferences, and Attitudes Poster II

9:00AM-11:00AM: Abstract Number: 1697

Unique Characteristics of Scleroderma Among African Americans: A Population Based Study

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster II

9:00AM-11:00AM: Abstract Number: 1336

Unique Role for miR429 in RA and Acute Model of Arthritis

Rheumatoid Arthritis – Animal Models Poster II

9:00AM-11:00AM: Abstract Number: 1200

Updating the Knee Osteoarthritis Intra-Articular Corticosteroid Meta-Analysis with Two Large Trials of Extended-Release Triamcinolone Acetonide (FX006) Versus Placebo

Osteoarthritis – Clinical Aspects Poster I: Clinical Trials and Interventions

9:00AM-11:00AM: Abstract Number: 1256

Uptake of Influenza and Pneumococcal Vaccination in Inflammatory Arthritis

Patient Outcomes, Preferences, and Attitudes Poster II

9:00AM-11:00AM: Abstract Number: 1137

Urate Lowering to ACR-Recommended Targets Allows Significant Improvement of Severe Gout: A Monocentric Prospective Trial in Vietnam, Using a Systematic Treatment Protocol

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 1136

Urate-Lowering Treatment and Risk of Total Joint Replacement in Patients with Incident Gout: A Population-Based Cohort and Nested Case-Control Study

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 1409

Ursolic Acid Promotes Apoptosis of Rheumatoid Athritis Synovial Fibroblasts By Upregulating Noxa Expression and Recruiting E3 Ligase Mule to Degrade Mcl-1

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1633

Use of Emergency Department (ED) and Resulting Hospitalization By Patients with Systemic Lupus Erythematosus (SLE) in a Predominantly Afro-Caribbean Inner-City Cohort

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities

9:00AM-11:00AM: Abstract Number: 1305

Use of Estrogen-Containing Contraceptives Among SLE Women with and without Contraindications to Estrogen

Reproductive Issues in Rheumatic Disorders Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].